Rising Thyroid Cancer Incidence in the United States by Demographic and Tumor Characteristics, 1980-2005

Abstract

Thyroid cancer incidence has been rising in the United States, and this trend has often been attributed to heightened medical surveillance and the use of improved diagnostics. Thyroid cancer incidence varies by sex and race/ethnicity, and these factors also influence access to and utilization of healthcare. We therefore examined thyroid cancer incidence rates by demographic and tumor characteristics based on 48,403 thyroid cancer patients diagnosed during 1980 -2005 from the Surveillance, Epidemiology and End Results program of the National Cancer Institute. The rates varied by histologic type, sex, and race/ ethnicity. Papillary carcinoma was the only histologic type for which incidence rates increased consistently among all racial/ethnic groups. Subsequent analyses focused on the 39,706 papillary thyroid cancers diagnosed during this period. Papillary carcinoma rates increased most rapidly among females. Between 1992 -1995 and 2003 -2005, they increased nearly 100% among White non-Hispanics and Black females but only 20% to 50% among White Hispanics, Asian/ Pacific Islanders, and Black males. The increases were most rapid for localized stage and small tumors; however, rates also increased for large tumors and tumors of regional and distant stage. Since 1992 -1995, half the overall increase in papillary carcinoma rates was due to increasing rates of very small (V1.0 cm) cancers, 30% to cancers 1.1 to 2 cm, and 20% to cancers >2 cm. Among White females, the rate of increase for cancers >5 cm almost equaled that for the smallest cancers. Medical surveillance and more sensitive diagnostic procedures cannot completely explain the observed increases in papillary thyroid cancer rates. Thus, other possible explanations should be explored. (Cancer Epidemiol Biomarkers Prev 2009;18(3):784 -91)

Decreasing tumor size of thyroid cancer in Germany: institutional experience 1995–2009

“…Before undergoing DNA-based screening, all patients or their legal guardians gave informed consent. Genomic DNA was purified from peripheral blood leukocytes using standard techniques, and amplified by means of PCR and oligonucleotide primers for exons 10,11,13,14,15 …”

Surgical Perspective of T1799A BRAF Mutation Diagnostic Value in Papillary Thyroid Carcinoma

“…Data analysis from Surveillance, Epidemiology, and End Results (SEER) estimated the incidence rate raised more than two folds with papillary thyroid carcinoma (PTC) is the most common pathological findings with the prevalence between 65-88% (Enewold et al, 2009). Throughout Indonesia, thyroid cancer is one of the ten most commonly found malignancies, comprising about 3.8% of all malignant cases (Tjindarbumi and Mangunkusumo, 2002).…”

Cumulative doses of radioiodine in the treatment of differentiated thyroid carcinoma: knowing when to stop

“…Arq Bras Endocrinol Metab. 2010;54(9):807-12 Descritores Dose cumulativa; radioiodoterapia; iodeto-131 I; carcinoma diferenciado de tiroide INTRODUCTION D ifferentiated thyroid cancer incidence has been rising all over the world and recent data demonstrate that rates have also increased for large and aggressive tumors diagnosed with distant metastasis (SEER stage) (1)(2)(3). Standard treatment for DTC patients includes total or near-total thyroidectomy followed by adjuvant radioiodine therapy (RIT) to destroy remnant, benign or malignant thyroid tissue (4)(5)(6).…”